Nisin
Overview
Nisin is a 34-amino acid polycyclic antibacterial peptide (lantibiotic) produced by Lactococcus lactis. It disrupts bacterial cell wall synthesis and forms pores in cell membranes by binding to lipid II, a precursor essential for peptidoglycan assembly. Its activity is primarily directed against Gram-positive bacteria, making it valuable in food preservation applications. The peptide contains unusual amino acids including lanthionine and beta-methyllanthionine, which confer structural stability and antimicrobial potency.
Key Research Findings
Nisin has been used as a food preservative for over 50 years and is designated as Generally Recognized As Safe (GRAS) by the FDA for food use. Clinical applications in human therapy remain investigational, with in vitro studies demonstrating activity against methicillin-resistant Staphylococcus aureus and other resistant pathogens. Topical and oral formulations are under preclinical evaluation for biofilm-associated infections and gastrointestinal decontamination.
Topical, Oral
Investigational
Interested in Nisin?
Find a verified provider experienced with Nisin protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Nisin ProviderRelated Peptides
Enfuvirtide (Fuzeon)
FDA ApprovedA 36-amino acid synthetic peptide that inhibits HIV-1 entry into CD4+ T-cells by blocking the gp41-mediated membrane fusion step. Enfuvirtide binds to the first heptad repeat (HR1) region of gp41, preventing the conformational change required for viral-cell membrane fusion. It is the first and only FDA-approved fusion inhibitor and is active against HIV-1 strains resistant to other antiretroviral drug classes.
Magainin 2
Research PhaseMagainin 2 is a 23-amino acid antimicrobial peptide originally isolated from the skin of the African clawed frog Xenopus laevis. It exerts broad-spectrum antimicrobial activity through membrane disruption, forming pores in bacterial membranes while exhibiting relative selectivity over mammalian cells. Magainin 2 belongs to the alpha-helical cationic antimicrobial peptide family and has served as a template for numerous synthetic analogs. Its mechanism of action, which is distinct from conventional antibiotics, offers potential against multidrug-resistant pathogens.
Pexiganan (MSI-78)
In Clinical TrialsPexiganan is a 22-amino acid synthetic analog of magainin 2 designed to enhance antimicrobial potency and proteolytic stability. It disrupts bacterial membranes through electrostatic interaction and pore formation, demonstrating broad-spectrum activity against gram-positive and gram-negative organisms, including methicillin-resistant Staphylococcus aureus. Pexiganan was developed as a topical agent for infected diabetic foot ulcers, leveraging its rapid bactericidal action and low resistance potential. Structural modifications from the parent magainin sequence improve its pharmacological profile for clinical use.
Omiganan
In Clinical TrialsOmiganan is a synthetic 12-amino acid cationic antimicrobial peptide derived from indolicidin, a naturally occurring peptide from bovine neutrophils. It acts by disrupting microbial membranes and demonstrates activity against bacteria, fungi, and some viruses. Omiganan was developed as a topical agent to prevent catheter-related bloodstream infections through its broad-spectrum antimicrobial properties. Its small size and potent activity made it a candidate for preventing biofilm formation on medical devices.